Compare ABM & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | ADMA |
|---|---|---|
| Founded | 1909 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 1994 | 2012 |
| Metric | ABM | ADMA |
|---|---|---|
| Price | $41.03 | $8.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $47.80 | $25.67 |
| AVG Volume (30 Days) | 340.3K | ★ 5.0M |
| Earning Date | 06-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 102.34 | N/A |
| EPS | ★ 0.64 | 0.19 |
| Revenue | ★ $8,745,900,000.00 | $42,219,783.00 |
| Revenue This Year | $5.97 | $27.46 |
| Revenue Next Year | $3.45 | $22.11 |
| P/E Ratio | $63.63 | ★ $16.74 |
| Revenue Growth | 4.62 | ★ 43.85 |
| 52 Week Low | $36.96 | $7.21 |
| 52 Week High | $52.94 | $22.37 |
| Indicator | ABM | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 26.09 |
| Support Level | $39.75 | $7.21 |
| Resistance Level | $46.34 | $16.02 |
| Average True Range (ATR) | 0.82 | 0.52 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 80.37 | 25.15 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.